DGX News Alert Quest Diagnostics Inc (DGX) 67.94 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Quest Diagnostics Inc (DGX) 67.94 $DGX

3 Healthcare Technologies That Are Set to Transform Our Lives Over the Next 10-20 Years
Motley Fool Staff - Motley Fool - Sat Dec 20, 5:45PM CST
Source: Touch Bionics. Cutting-edge technology could reshape healthcare over the coming 10-20 years, in the process curbing runaway spending and improving the lives of millions of patients. Which technologies might move the needle most? Three...
DXCM: 54.94 (+0.99), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), WAG: 76.67 (+0.16)

Pacific Biosciences Appoints Kathy Ordonez to Board of Directors
GlobeNewswire - Thu Dec 18, 11:56AM CST
Pacific Biosciences of California, Inc., (Nasdaq ACB) provider of the PacBio RS II Sequencing System, today announced that it has appointed industry veteran Kathy Ordonez to its Board of Directors. Ordonez has a 30 year history of leadership in the life sciences and diagnostics industries, including positions as Senior Vice President of Quest Diagnostics, Chief Executive Officer of Celera, founder of Celera Diagnostics, and President and Chief Executive Officer for Roche Molecular Systems.
PACB: 7.46 (+0.01), DGX: 67.94 (-0.16)

RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
GlobeNewswire - Thu Dec 18, 5:05AM CST
-- The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients
RDHL: 12.22 (-0.13), DGX: 67.94 (-0.16)

Meet 5 Big Tech Stocks Expected To See Profits Surge
at Investor's Business Daily - Tue Dec 16, 8:03PM CST
With the stock market again correcting, investors should be looking to create stock watch lists for the next uptrend. Fast-growing, large-capitalization companies are a good place to look. Today's Screen Of The Day is Big Cap Leaders, large companies...
GPRO: 66.41 (+4.87), SWKS: 74.32 (+0.92), GILD: 91.29 (+1.84), DGX: 67.94 (-0.16), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), ILMN: 186.22 (+2.72), GM: 33.43 (-0.13), TSM: 22.35 (+0.14), NXPI: 76.75 (+0.48), COL: 86.16 (+0.28), AAPL: 112.01 (-0.53), AVGO: 100.72 (-0.06), BABA: 105.95 (+0.43)

2 Large Blood Testing Companies Stand To Be Disrupted
Paulo Santos - at Seeking Alpha - Tue Dec 16, 9:32AM CST

DGX: 67.94 (-0.16), LH: 107.69 (+0.56)

Cervical Cancer Diagnostic Tests Market - 2014 Global Industry Analysis
M2 - Tue Dec 16, 5:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/q8j6pp/cervical_cancer) has announced the addition of the "Cervical Cancer Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends" report to their offering. The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations. Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp., Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles For more information visit http://www.researchandmarkets.com/research/q8...cal_cancer
DGX: 67.94 (-0.16), QGEN: 23.20 (+0.09), HOLX: 26.89 (+0.10)

United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 14.90 (+0.05), HH: 0.53 (unch), BRLI: 31.82 (+0.55), NEO: 4.03 (-0.10), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), GHDX: 32.44 (+1.32)

United States Ambulatory Health Care Services Industry Analytics 2014-2021: Market to reach $1.4 trillion by 2021
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/kcxkrm/ambulatory_health) has announced the addition of Plunkett Research Ltd's new report "Ambulatory Health Care Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Ambulatory Health Care Services Industry (U.S.) to reach $1.4 trillion by 2021. - Ambulatory Health Care Services Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Apria Healthcare Group Inc - DaVita Healthcare Partners Inc - Fresenius Medical Care North America - HealthSouth Corp - Laboratory Corp of America Holdings - Lincare Holdings Inc - MEDNAX Inc - Magellan Health Inc - Quest Diagnostics Inc - Team Health Holdings Inc For more information visit http://www.researchandmarkets.com/research/kc...ory_health Source: Plunkett Research Ltd
DGX: 67.94 (-0.16), LH: 107.69 (+0.56), HLS: 40.45 (+0.12), MD: 66.81 (+0.17)

United States Medical and Diagnostic Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6lcqc/medical_and) has announced the addition of Plunkett Research Ltd's new report "Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical and Diagnostic Laboratories Industry (U.S.) to reach $80.8 billion by 2021. - Medical and Diagnostic Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alliance Healthcare Services Inc - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - NeoGenomics Inc - Quest Diagnostics Inc - RadNet Inc For more information visit http://www.researchandmarkets.com/research/k6...edical_and Source: Plunkett Research Ltd
HH: 0.53 (unch), BRLI: 31.82 (+0.55), RDNT: 9.41 (-0.08), NEO: 4.03 (-0.10), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), GHDX: 32.44 (+1.32)

Quest Diagnostics' Virus Test Kit Wins FDA Clearance Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:40PM CST
Studies conducted by Quest Diagnostics (DGX) over time have shown that the Simplexa test kit can offer fast, reliable results within an hour.
CHE: 106.16 (+0.13), AFAM: 29.53 (-0.06), DGX: 67.94 (-0.16), AMED: 28.97 (-0.08)

Bio-Reference Laboratories Tested: Undisclosed Lawsuit Alleges Fraud, Ex-Employees Speak Out
The GeoTeam - Seeking Alpha - Wed Dec 10, 9:15AM CST
By now, some of the extremely obvious risks to investing in Bio-Reference Laboratories (NASDAQ: BRLI ) have been in the public domain for a while. Questions have been raised about ties to organized crime, stuffing envelopes full of cash for...
BRLI: 31.82 (+0.55), DGX: 67.94 (-0.16), LH: 107.69 (+0.56)

FDA Clears the Focus Diagnostics Simplexa(TM) Flu A/B & RSV Direct Test to Include Eight Circulating Influenza Viruses
PR Newswire - Tue Dec 09, 8:21AM CST
As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics (NYSE: DGX), today announced that its Simplexa(TM) Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter. The FDA, which granted 510(k) clearance to the test kit originally in July 2012, cleared additional analytical reactivity to include Flu A H7N9 and H3N2v, among other strains, based on studies that demonstrated the test's analytical performance.
DGX: 67.94 (-0.16)

Look for Shares of Quest Diagnostics to Potentially Rebound after Yesterday's 1.78% Sell Off
Comtex SmarTrend(R) - Thu Dec 04, 3:58PM CST
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $64.16 to a high of $65.89. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $64.51 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 67.94 (-0.16)

Quest Diagnostics declares $0.33 dividend
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 12:29PM CST

DGX: 67.94 (-0.16)

Quest Diagnostics Declares Quarterly Cash Dividend
PR Newswire - Thu Dec 04, 12:15PM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.33 per share, payable on January 28, 2015 to shareholders of record of Quest Diagnostics common stock on January 13, 2015.
DGX: 67.94 (-0.16)

Quest Diagnostics To Speak At The Piper Jaffray 26th Annual Healthcare Conference
PR Newswire - Mon Dec 01, 10:18AM CST
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Piper Jaffray 26th Annual Healthcare Conference in New York City. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, December 2, 2014 at 9:30 a.m. Eastern Time.
DGX: 67.94 (-0.16)

Global Bioinformatics Market Outlook 2020 for the $12 Billion Industry
M2 - Wed Nov 26, 2:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/6f3prw/global) has announced the addition of the "Global Bioinformatics Market Outlook 2020 for the $12 Billion Industry" report to their offering. The bioinformatics market is expected to grow to $12.86 billion by 2020 with a CAGR of 21.2% during 2014-2020 Bioinformatics is an interdisciplinary field that is used in the development and storage of data, thus helping in the analysis, organization and retrieval of the biological data. Bioinformatics has various applications and thus forms part of almost all the fields in biology. Bioinformatics form a part of agriculture, animal breeding, molecular medicine, preventive medicine, etc. The major factors driving the bioinformatics market is the need for integrated data, rising demand for drug development and discovery, the increasing focus in genomics & proteomics and the favorable government initiatives. The factor limiting this market is the need for skilled personnel due to the complexity of the bioinformatics tools used. The other limiting factors are the saturation of the pharmaceutical sectors and lack of common data formats. The factors that would provide opportunity for the growth of this market are standardization of databases, need for integration systems and solutions and need to control data overload due to the piling-up of data due to the numerous experiments conducted. The reason to study this market is to understand the current trends and applications in the bioinformatics field along with in depth analysis of the segments. Scope of the Report TECHNOLOGY - Knowledge Management Tools - Generalized knowledge management tools - Specialized knowledge management tools - Bioinformatics Platforms - Sequence analysis platforms - Sequence alignment platforms - Sequence manipulation platforms - Structural analysis platforms SERVICES - Bioinformatics Services - Sequencing services - Database and management - Data Analysis BY APPLICATION - Metabolomics - Molecular Phylogenetics - Transcriptomics - Proteomics - Chemoinformatics - Genomics BY SECTOR - Medical Bioinformatics - Animal Bioinformatics - Agriculture Bioinformatics - Academics Companies Mentioned - Accelrys - Affymetrix - Agilent technologies - Biomax informatics AG. - Bruker Daltonics - Geneva bioinformatics - Illumina - Life Technologies corp. - Non linear dynamics - Quest Diagnostics For more information visit http://www.researchandmarkets.com/research/6f3prw/global
DGX: 67.94 (-0.16)

ACLA Retains Attorneys Paul D. Clement and Laurence H. Tribe To Represent ACLA in Opposing the FDA's Proposal To Treat Laboratory Developed Tests (LDTs) as Medical Devices
PR Newswire - Tue Nov 18, 8:51AM CST
The American Clinical Laboratory Association (ACLA) announced today that it has retained former Solicitor General Paul D. Clement, a partner with Bancroft PLLC, and Laurence H. Tribe, the Carl. M. Loeb University Professor and Professor of Constitutional Law at Harvard University, and a distinguished scholar working with Massey & Gail LLP, for representation on matters relating to the Food and Drug Administration's (FDA) recently issued draft guidance to regulate laboratory developed tests (LDTs) as medical devices.
DGX: 67.94 (-0.16)

OPTIMIZERx Corp. to Automate Patient Savings and Improve Medication Adherence for Patients Served by Providers Utilizing Care360 ePrescribing From Quest Diagnostics
Marketwired - Mon Nov 17, 6:05AM CST
OPTIMIZERx Corp. (OTCQB: OPRX) announced Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will leverage OptimizeRx's technology to automate prescriber access to electronic coupons within Quest Diagnostics' Care360 e-prescribing solutions.
DGX: 67.94 (-0.16)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 31

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 179

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 75

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 86

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 73

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 5

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 46

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 111

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
McDonald's Franchise Wage Suit Puts Compliance on Notice

Updated Category News Views 129

Payroll sloppiness can turn a cheap burger shift into an expensive courtroom problem fast. Zakay Law Group, APLC has filed a proposed class action in Alameda County Superior Court against a long list of McDonald's franchise-related entities, alleging workers were not paid all wages due under California law. The case, 26CV218760, is pending, not proven, and that...

Continue Reading

Top 5 Most Recently Viewed Articles

PI Strengthens U.S. Manufacturing with New Facility Opening

Updated Category News Views 277

PI Enhances U.S. Manufacturing Capabilities PI (Physik Instrumente) is making significant strides in its operations by expanding its manufacturing capabilities in the United States. This move, aimed at strengthening its customer support, comes as the company prepares to open a new production facility soon. The expansion is a strategic response to current trade challenges...

Continue Reading
Revolutionizing K-12 Education with RightFind Curriculum

Updated Category News Views 157

Introducing the RightFind Curriculum by CCC CCC, a leader in copyright innovation, has launched its newest solution: the RightFind Curriculum. This tool is designed to help integrate high-quality, copyrighted materials into K-12 educational settings. It specifically caters to educators, EdTech companies, and curriculum developers, making it easier to search for and use...

Continue Reading
Essential Tips for Homebuyers During Peak Season

Updated Category News Views 157

Essential Tips for Homebuyers During Peak Season Spring is often seen as the height of the homebuying season. Many buyers aim to purchase homes and settle in before the summer months, especially before the new school year approaches. To assist homebuyers in navigating this critical time, the Pennsylvania Association of Realtors has shared useful insights. The Importance...

Continue Reading
Wolfspeed Faces Securities Fraud Lawsuit: What Investors Should Know

Updated Category News Views 926

Wolfspeed, Inc. Under Securities Fraud Investigation As many investors navigate turmoil in the stock market, a recent development concerning Wolfspeed, Inc. is drawing significant attention. Block & Leviton has announced that a lawsuit for securities fraud has been filed against Wolfspeed, Inc. (WOLF) and several of its executives. For those who have experienced financial...

Continue Reading
Ero Copper Corp. Set to Announce Q3 Results This November

Updated Category News Views 210

Ero Copper Corp. Prepares for Q3 Financial Results Release VANCOUVER, British Columbia – Excitement is building for Ero Copper Corp. (TSX: ERO, NYSE: ERO) as the company is set to publish its operating and financial results for the third quarter of 2025 on November 4. This announcement will occur after the market closes, providing valuable insights into the company’s...

Continue Reading